S'abonner

CELL DEATH AT THE MILLENNIUM : Implications for Liver Diseases - 05/09/11

Doi : 10.1016/S1089-3261(05)70094-5 
Neil Kaplowitz, MD *

Résumé

The past 5 years or so have witnessed an explosion of interest and information concerning the processes that participate in the demise of cells. For many years, in the field of hepatology, two morphological patterns of lethal injury have been recognized: zonal coagulative necrosis and spotty shrinkage necrosis (Councilman bodies). Little significance was attributed to this morphological distinction until the work of Kerr in the early 1970s. Kerr recognized that hepatic atrophy following ligation of the portal vein was accompanied by loss of cells through a process of condensation and fragmentation of cells,50 followed by their separation from neighbors and phagocytosis. Kerr and his associates subsequently referred to this process as apoptosis,51 a Greek word referring to the dropping of petals from flowers or leaves from trees. Recently, the mechanisms and regulation of the process became accessible through the tools of modern molecular and cellular biology. Now the study of cell death has become one of the most rapidly advancing fields of biology, and translational applications in all fields of medicine are likely by the beginning of the next millenium.

Two fundamental types of cell death have been distinguished: necrosis and apoptosis. Necrosis involves loss of ATP, swelling of cells, lysis, and secondary inflammation. Apoptosis involves preservation of ATP (at least initially), shrinkage, cytoplasmic and nuclear condensation and fragmentation, and rapid phagocytic removal by macrophages and epithelial cells, with little inflammation. In the liver, necrosis tends to be zonal, whereas apoptosis tends to be spotty.

The question arises as to whether these two types of cell death are as distinct as their morphology would suggest. Although this issue will be discussed in detail later, the short answer is that the manner of cell death appears to represent a spectrum of responses to the same stimuli, such as cytokines and toxins. Although apoptosis is a fundamental and specific mode of cell death in certain normal biologic processes, such as development and tissue turnover (so-called programmed cell death), in disease processes it is less certain that the manner of cell death is as important as its cause. Undoubtedly there exist certain noxious events (mild hypoxia or oxidative stress) that are relatively mild but that activate the quiescent components of the cell-death program. In contrast, there are more massive assaults (e.g., marked oxidative stress or anoxia) that kill the cells quickly by necrosis. There are also, however, intermediate situations which appear to induce apoptosis preferentially, but that lead to necrosis when the apoptosis execution program is blocked, thus demonstrating the inevitability of cell death. Indeed, both apoptosis and necrosis may be seen in different cells in the liver at the same time. This observation is further complicated because massive apoptosis can overwhelm the phagocytic removal of fragmented cells, which then may remain in situ and undergo morphological changes indistinguishable from coagulative necrosis (i.e., secondary necrosis), making it difficult for the pathologist to determine which type of cell death had occurred originally. In summary, apoptosis occurs physiologically in development and tissue turnover, and mild to moderate exposure to reactive oxygen metabolites, hypoxia, or toxins can activate the built-in death program. Severer exposures may be directly lethal, causing necrosis while inhibiting the apoptosis death program. Intermediate situations can occur in which the cell is committed to death whether the apoptosis machinery is active or inhibited.

Le texte complet de cet article est disponible en PDF.

Plan


 Address reprint requests to Neil Kaplowitz, MD, University of Southern California School of Medicine, 2011 Zonal Avenue, HMR 101, Los Angeles, CA 90033


© 2000  W. B. Saunders Company. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 4 - N° 1

P. 1-23 - février 2000 Retour au numéro
Article précédent Article précédent
  • PREFACE
  • NORMAN GITLIN
| Article suivant Article suivant
  • FULMINANT HEPATIC FAILURE
  • Stephen M. Riordan, Roger Williams

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.